vs

Side-by-side financial comparison of Peraso Inc. (PRSO) and Vivos Therapeutics, Inc. (VVOS). Click either name above to swap in a different company.

Vivos Therapeutics, Inc. is the larger business by last-quarter revenue ($3.8M vs $2.9M, roughly 1.3× Peraso Inc.). Peraso Inc. runs the higher net margin — -43.3% vs -180.3%, a 136.9% gap on every dollar of revenue. On growth, Vivos Therapeutics, Inc. posted the faster year-over-year revenue change (3.4% vs -22.0%). Over the past eight quarters, Vivos Therapeutics, Inc.'s revenue compounded faster (5.8% CAGR vs 1.0%).

Peraso Inc. is a semiconductor technology firm specializing in the design and production of high-performance millimeter wave (mmWave) integrated circuits and modules. It delivers 5G and next-generation wireless connectivity solutions for telecom infrastructure, industrial IoT, fixed wireless access and consumer electronics segments, serving customers across North America, Asia Pacific and European markets.

Beam Therapeutics Inc. is an American biotechnology company conducting research in the field of gene therapies and genome editing. The company is headquartered in Cambridge, Massachusetts. In the development of therapies, the company relies on CRISPR base editing and prime editing, whereby single nucleotides in a DNA sequence can be enzymatically modified without producing double-strand breaks.

PRSO vs VVOS — Head-to-Head

Bigger by revenue
VVOS
VVOS
1.3× larger
VVOS
$3.8M
$2.9M
PRSO
Growing faster (revenue YoY)
VVOS
VVOS
+25.4% gap
VVOS
3.4%
-22.0%
PRSO
Higher net margin
PRSO
PRSO
136.9% more per $
PRSO
-43.3%
-180.3%
VVOS
Faster 2-yr revenue CAGR
VVOS
VVOS
Annualised
VVOS
5.8%
1.0%
PRSO

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
PRSO
PRSO
VVOS
VVOS
Revenue
$2.9M
$3.8M
Net Profit
$-1.2M
$-6.9M
Gross Margin
52.2%
78.1%
Operating Margin
-44.6%
-166.8%
Net Margin
-43.3%
-180.3%
Revenue YoY
-22.0%
3.4%
Net Profit YoY
20.3%
-143.8%
EPS (diluted)
$-0.09
$-0.58

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PRSO
PRSO
VVOS
VVOS
Q4 25
$2.9M
$3.8M
Q3 25
$3.2M
$6.8M
Q2 25
$2.2M
$3.8M
Q1 25
$3.9M
$3.0M
Q4 24
$3.7M
$3.7M
Q3 24
$3.8M
$3.9M
Q2 24
$4.2M
$4.1M
Q1 24
$2.8M
$3.4M
Net Profit
PRSO
PRSO
VVOS
VVOS
Q4 25
$-1.2M
$-6.9M
Q3 25
$-1.2M
$-5.4M
Q2 25
$-1.8M
$-5.0M
Q1 25
$-471.0K
$-3.9M
Q4 24
$-1.6M
$-2.8M
Q3 24
$-2.7M
$-2.6M
Q2 24
$-4.4M
$-1.9M
Q1 24
$-2.0M
$-3.8M
Gross Margin
PRSO
PRSO
VVOS
VVOS
Q4 25
52.2%
78.1%
Q3 25
56.2%
58.0%
Q2 25
48.3%
55.2%
Q1 25
69.3%
50.0%
Q4 24
56.3%
56.7%
Q3 24
47.0%
60.5%
Q2 24
55.5%
65.4%
Q1 24
46.4%
56.7%
Operating Margin
PRSO
PRSO
VVOS
VVOS
Q4 25
-44.6%
-166.8%
Q3 25
-36.8%
-69.8%
Q2 25
-80.0%
-127.4%
Q1 25
-13.3%
-129.9%
Q4 24
-44.3%
-75.9%
Q3 24
-70.3%
-68.5%
Q2 24
-105.6%
-47.8%
Q1 24
-128.9%
-110.7%
Net Margin
PRSO
PRSO
VVOS
VVOS
Q4 25
-43.3%
-180.3%
Q3 25
-37.4%
-79.6%
Q2 25
-82.4%
-131.2%
Q1 25
-12.2%
-128.1%
Q4 24
-42.4%
-76.4%
Q3 24
-70.6%
-67.8%
Q2 24
-104.4%
-47.6%
Q1 24
-72.1%
-110.1%
EPS (diluted)
PRSO
PRSO
VVOS
VVOS
Q4 25
$-0.09
$-0.58
Q3 25
$-0.17
$-0.49
Q2 25
$-0.31
$-0.55
Q1 25
$-0.10
$-0.45
Q4 24
$0.36
$0.41
Q3 24
$-0.98
$-0.40
Q2 24
$-1.88
$-0.60
Q1 24
$-1.07
$-1.63

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PRSO
PRSO
VVOS
VVOS
Cash + ST InvestmentsLiquidity on hand
$2.9M
$2.0M
Total DebtLower is stronger
$2.9M
Stockholders' EquityBook value
$4.6M
$-1.5M
Total Assets
$6.1M
$25.2M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PRSO
PRSO
VVOS
VVOS
Q4 25
$2.9M
$2.0M
Q3 25
$3.1M
Q2 25
$4.4M
Q1 25
$2.3M
Q4 24
$3.3M
$6.3M
Q3 24
$1.3M
$6.3M
Q2 24
$1.9M
$6.9M
Q1 24
$2.4M
$2.6M
Total Debt
PRSO
PRSO
VVOS
VVOS
Q4 25
$2.9M
Q3 25
Q2 25
Q1 25
Q4 24
$1.2M
Q3 24
$1.2M
Q2 24
$1.2M
Q1 24
Stockholders' Equity
PRSO
PRSO
VVOS
VVOS
Q4 25
$4.6M
$-1.5M
Q3 25
$3.6M
$2.5M
Q2 25
$3.0M
$4.6M
Q1 25
$3.6M
$4.4M
Q4 24
$3.5M
$8.0M
Q3 24
$2.0M
$7.7M
Q2 24
$3.6M
$6.3M
Q1 24
$6.7M
$582.0K
Total Assets
PRSO
PRSO
VVOS
VVOS
Q4 25
$6.1M
$25.2M
Q3 25
$6.2M
$25.6M
Q2 25
$5.5M
$26.0M
Q1 25
$6.7M
$11.3M
Q4 24
$7.2M
$15.3M
Q3 24
$7.2M
$15.3M
Q2 24
$9.8M
$15.8M
Q1 24
$11.5M
$11.8M
Debt / Equity
PRSO
PRSO
VVOS
VVOS
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.15×
Q3 24
0.16×
Q2 24
0.19×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PRSO
PRSO
VVOS
VVOS
Operating Cash FlowLast quarter
$-1.1M
$-3.8M
Free Cash FlowOCF − Capex
$-5.3M
FCF MarginFCF / Revenue
-139.7%
Capex IntensityCapex / Revenue
40.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-17.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PRSO
PRSO
VVOS
VVOS
Q4 25
$-1.1M
$-3.8M
Q3 25
$-1.5M
$-4.2M
Q2 25
$-2.0M
$-3.5M
Q1 25
$-966.0K
$-3.8M
Q4 24
$-687.0K
$-2.9M
Q3 24
$-683.0K
$-4.2M
Q2 24
$-659.0K
$-3.0M
Q1 24
$-2.5M
$-2.5M
Free Cash Flow
PRSO
PRSO
VVOS
VVOS
Q4 25
$-5.3M
Q3 25
$-1.6M
$-4.2M
Q2 25
$-4.3M
Q1 25
$-3.9M
Q4 24
$-3.1M
Q3 24
$-4.4M
Q2 24
$-3.1M
Q1 24
$-2.7M
FCF Margin
PRSO
PRSO
VVOS
VVOS
Q4 25
-139.7%
Q3 25
-48.9%
-62.6%
Q2 25
-111.6%
Q1 25
-129.9%
Q4 24
-84.0%
Q3 24
-113.4%
Q2 24
-76.7%
Q1 24
-78.0%
Capex Intensity
PRSO
PRSO
VVOS
VVOS
Q4 25
40.0%
Q3 25
1.1%
1.2%
Q2 25
20.2%
Q1 25
4.0%
Q4 24
4.5%
Q3 24
5.0%
Q2 24
1.5%
Q1 24
4.4%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

PRSO
PRSO

Products$2.8M96%
Other$105.0K4%

VVOS
VVOS

Services$3.2M84%
Products$594.0K16%

Related Comparisons